Post by account_disabled on Feb 28, 2024 6:49:03 GMT
They put the wolf to guard the lambs” The high price of new medicines set by laboratories without information on the cost of their research and manufacturing will put the economic sustainability of health systems at risk. pharmaceuticals Newtribuna NT | :00 We need your help to continue reporting Become a member of Nuevatribuna The Federation of Associations in Defense of Public Health has made public its critical position regarding the approval, in the European Parliament Commission, of the proposal for the Pharmaceutical Strategy of the European Union. The European Parliament Committee has approved the European Union Pharmaceutical Strategy to update the legislation and the incentive system for new medicines. This strategy aims to promote the construction of the new European Union for Health , through different instruments: the European Union for Health Program 2021-2027, which has a budget of.
billion euros ten times larger than the previous one, the New Strategy European Pharmaceutical or the Next Generation Funds. The speaker was Dolors Monserrat , spokesperson for the Popular Party in Malta Phone Number Parliament, a lawyer specialized in urban planning, real estate and environmental law, who was Minister of Health, Social Services and Equality in the government of Mariano Rajoy from 2016 and and, as FADSP points out, , "faithful executor of its neoliberal policy of cuts to the Public Health System and support for the private sector," says Manuel Martín, president of the FADSP , who warns that "they put the wolf to take care of the lambs." Have you read this? Insulin, a scientific advance. T
Importance of public pharmaceutical companies pharmaceutical lobbies From the analysis of this strategy, the health organization considers in its report that the speaker and her team “have been very permeable to the pressure of the lobbies of the powerful laboratories and multinational health technology companies that seek to put the European Union at the service of their interests". There are 3,848 entities represented before the Commission that declared interest in Public Health and held 1,356 meetings with senior officials of the European Union. The European Federation of Pharmaceutical Industries defends the interests of pharmaceutical companies and brings together large pharmaceutical companies and laboratories such as AstraZeneca, Pfizer, Merck, Sanofi, Gilead or Bayer and held 86 meetings with the Commission and spends 36 million euros a year to make lobby in the EU.
billion euros ten times larger than the previous one, the New Strategy European Pharmaceutical or the Next Generation Funds. The speaker was Dolors Monserrat , spokesperson for the Popular Party in Malta Phone Number Parliament, a lawyer specialized in urban planning, real estate and environmental law, who was Minister of Health, Social Services and Equality in the government of Mariano Rajoy from 2016 and and, as FADSP points out, , "faithful executor of its neoliberal policy of cuts to the Public Health System and support for the private sector," says Manuel Martín, president of the FADSP , who warns that "they put the wolf to take care of the lambs." Have you read this? Insulin, a scientific advance. T
Importance of public pharmaceutical companies pharmaceutical lobbies From the analysis of this strategy, the health organization considers in its report that the speaker and her team “have been very permeable to the pressure of the lobbies of the powerful laboratories and multinational health technology companies that seek to put the European Union at the service of their interests". There are 3,848 entities represented before the Commission that declared interest in Public Health and held 1,356 meetings with senior officials of the European Union. The European Federation of Pharmaceutical Industries defends the interests of pharmaceutical companies and brings together large pharmaceutical companies and laboratories such as AstraZeneca, Pfizer, Merck, Sanofi, Gilead or Bayer and held 86 meetings with the Commission and spends 36 million euros a year to make lobby in the EU.
